Synageva BioPharma (GEVA)

[rsox]

here is a little reading on the so called fuzeon affect that the execs at trimeris were boasting about at the jan 31 fuzeon sales update...

27.07.2005 - 12:39 Uhr
Rio De Janeiro, Brazil (ots/PRNewswire) -

- Giving Patients Facing HIV Resistance Their Best Chance to
Achieve Undetectable Viral Loads

Data presented at IAS build a compelling case for FUZEON
(enfuvirtide, formerly known as T-20) to be combined with the newest
drugs to give patients facing resistance their best chance of
achieving undetectable viral load - the optimal treatment goal for
all people living with HIV.

"Undetectable viral load should be the ultimate treatment goal for
all triple-class experienced patients. FUZEON combined with the
latest drugs now makes this much more achievable," explained Dr Mike
Youle the Royal Free Hospital, London. "We are seeing a consistent
FUZEON effect with these new drugs and I believe these data must
change the way we manage triple class experienced patients facing HIV
resistance and failing to reach undetectable viral load."

Studies presented this week show that when FUZEON was given in
combination with the novel HIV medication, tipranavir, an impressive
70% of FUZEON naïve patients achieved a ten-fold reduction in their
viral load and furthermore they also had double the increase in
immune cell count(1), compared to patients receiving tipranavir/r
without FUZEON.